tradingkey.logo
搜索

Eton Pharmaceuticals Inc

ETON
添加自选
46.420USD
-2.610-5.32%
收盘 07-31 16:00美东报价延迟15分钟
1.27B总市值
亏损市盈率 TTM

关于 Eton Pharmaceuticals Inc 公司

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Eton Pharmaceuticals Inc简介

公司代码ETON
公司名称Eton Pharmaceuticals Inc
上市日期Nov 09, 2018
CEOBrynjelsen (Sean E)
员工数量31
证券类型Ordinary Share
年结日Nov 09
公司地址21925 W Field Pkwy Ste 235
城市DEER PARK
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编60010-7278
电话18477877361
网址https://etonpharma.com/
公司代码ETON
上市日期Nov 09, 2018
CEOBrynjelsen (Sean E)

Eton Pharmaceuticals Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.06M
+21.54%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--
Ms. Jennifer (Jenn) Adams
Ms. Jennifer (Jenn) Adams
Independent Director
Independent Director
--
--
Mr. David C. Krempa
Mr. David C. Krempa
Chief Business Officer
Chief Business Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.06M
+21.54%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--

常见问题

Eton Pharmaceuticals Inc的前五大股东是谁?

Eton Pharmaceuticals Inc 的前五大股东如下:Mr. Sean E. Brynjelsen

有多少机构持有Eton Pharmaceuticals Inc(ETON)的股份?

截至2026Q1,共有235家机构持有Eton Pharmaceuticals Inc的股份,合计持有的股份价值约为15.99M,占公司总股份的58.43%。与2025Q4相比,机构持股有所增加,增幅为-3678435.00。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有